Abstract:Abstract Background Microparticles (MPs) are extracellular vesicles that are associated with cancer development and progression. Advanced non-small cell lung cancer (NSCLC) still shows disease progression after multiple lines of treatment. Therefore, the objective of this study was to explore the correlation between circulating MPs and disease progression in advanced NSCLC, and to find a new method for concise and rapid determination of disease progression. Methods Patients with advanced NSCLC admitted to hospital between October 2019 and October 2020 were included and divided into objective remission (OR) and progressive disease (PD) groups. The morphology of MPs was observed using transmission electron microscopy. The circulating total MPs, neutrophil MPs (NMPs), and platelet MPs (PMPs) before and after treatment were detected by flow cytometry, and a predictive model for disease progression in advanced NSCLC was developed. Results Eighty-six patients were included; 60 in the OR group and 26 in the PD group. There was no significant difference in total MPs, NMPs, or PMPs at baseline between the two groups. After treatment, total MPs, NMPs, and PMPs were significantly higher in the PD than those in the OR group. Multivariate regression analysis showed that post-treatment NMPs≥160 events/μL(OR,3.748;95%CI,1.147–12.253,p = 0.029), PMPs≥80 events/μL(OR,10.968;95%CI,2.973–40.462,p < 0.0001) and neutrophil/lymphocyte ratio (NLR) ≥3.3 (OR,4.929;95%CI,1.483–16.375,p = 0.009) were independently associated with progression of advanced NSCLC. Post-treatment NMPs and PMPs combined with NLR were used to build a predictive model for progression of advanced NSCLC. The area under the curve was 0.825 (95%CI,0.715–0.934, p < 0.0001), optimal cut-off value was 16, sensitivity was 80.8%, and specificity was 88.3%. Conclusion NMPs and PMPs are associated with progression of advanced NSCLC. The predictive model for progression of advanced NSCLC, established combining NMPs, PMPs, and NLR, can screen out 80.8% of patients with PD. This is helpful for real-time accurate, concise and rapid assessment of disease progression and timely adjustment of drug therapy. Trial registration Chinese Clinical Trial Registry, ChiCTR1800020223 . Registered 20 December 2018, http://www.chictr.org.cn/index.aspx .

Circulating Microparticles Are Prognostic Biomarkers in Advanced Non-Small Cell Lung Cancer Patients

Circulating Endothelial-Derived Activated Microparticle: A Useful Biomarker for Predicting One-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer

Predicting Disease Progression in Advanced Non-Small Cell Lung Cancer with Circulating Neutrophil-Derived and Platelet-Derived Microparticles.

Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention

P2.03b-092 Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy: Topic: Biomarkers

Prediction Of The Therapeutic Effects Of Pembrolizumab And Nivolumab In Advanced Non-Small Cell Lung Cancer By Platelet-Derived Microparticles In Circulating Blood

Folate Receptor-Positive Circulating Tumor Cells As a Predictive Biomarker for the Efficacy of First-Line Pemetrexed-Based Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in Egfr Mutation/Alk Translocation Metastatic Non-Small Cell Lung Cancer

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

Prognostic Importance of Circulating Tumor Cells in Non-Small Cell Lung Cancer: A Prospective Study

Circulating Tumor Cells Dynamics During Chemotherapy Predict Survival and Response in Advanced Non-Small-cell Lung Cancer Patients.

Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC)

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy

Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

Circulating Biomarkers for Early Stage Non-Small Cell Lung Carcinoma Detection: Supplementation to Low‐Dose Computed Tomography

The Potential Applications of Microparticles in the Diagnosis, Treatment, and Prognosis of Lung Cancer

Circulating Plasma Mirnas As Potential Biomarkers of Non-Small Cell Lung Cancer Obtained by High-Throughput Real-Time PCR Profiling

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer

Dynamic Changes of Circulating Tumor Cells During Chemotherapy As a Prognostic Factor in Patients with Advanced Lung Cancer.

Circulating Tumor DNA Clearance Predicts Prognosis Across Treatment Regimen in a Large Real-World Longitudinally Monitored Advanced Non-Small Cell Lung Cancer Cohort.

The detection of circulating tumor cells indicates poor therapeutic efficacy and prognosis in patients with nonsmall cell lung cancer: A systematic review and meta‐analysis